Notification of Major Interest – Lanstead Increases Holding to over 5%

5th February 2018 - 2:37 pm

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has received notification that Lanstead Capital LP (“Lanstead”) has confirmed an increase in its holding in ImmuPharma. Lanstead now holds 6,985,893 Ordinary shares of 10p each in the Com-pany, representing 5.01% of ImmuPharma’s issued share capital of 139,467,430 Ordinary shares with voting rights.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Share this article

Leave a comment